Literature DB >> 23038671

Roles of CUB and LDL receptor class A domain repeats of a transmembrane serine protease matriptase in its zymogen activation.

Kuniyo Inouye1, Marie Tomoishi, Makoto Yasumoto, Yuka Miyake, Kenji Kojima, Satoshi Tsuzuki, Tohru Fushiki.   

Abstract

Matriptase is a type II transmembrane serine protease containing two complement proteases C1r/C1s-urchin embryonic growth factor-bone morphogenetic protein domains (CUB repeat) and four low-density lipoprotein receptor class A domains (LDLRA repeat). The single-chain zymogen of matriptase has been found to exhibit substantial protease activity, possibly causing its own activation (i.e. conversion to a disulfide-linked two-chain fully active form), although the activation seems to be mediated predominantly by two-chain molecules. Our aim was to assess the roles of CUB and LDLRA repeats in zymogen activation. Transient expression studies of soluble truncated constructs of recombinant matriptase in COS-1 cells showed that the CUB repeat had an inhibitory effect on zymogen activation, possibly because it facilitated the interaction of two-chain molecules with a matriptase inhibitor, hepatocyte growth factor activator inhibitor type-1. By contrast, the LDLRA repeat had a promoting effect on zymogen activation. The effect of the LDLRA repeat seems to reflect its ability to increase zymogen activity. The proteolytic activities were higher in pseudozymogen forms of recombinant matriptase containing the LDLRA repeat than in a pseudozymogen without the repeat. Our findings provide new insights into the roles of these non-catalytic domains in the generation of active matriptase.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23038671      PMCID: PMC3527997          DOI: 10.1093/jb/mvs118

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  31 in total

1.  The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.

Authors:  Michael D Oberst; Cicely A Williams; Robert B Dickson; Michael D Johnson; Chen-Yong Lin
Journal:  J Biol Chem       Date:  2003-05-08       Impact factor: 5.157

2.  Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells.

Authors:  Yuka Miyake; Satoshi Tsuzuki; Makoto Yasumoto; Tohru Fushiki; Kuniyo Inouye
Journal:  Cytotechnology       Date:  2009-08-05       Impact factor: 2.058

Review 3.  The alpha 2-macroglobulin receptor and epithelial glycoprotein-330: two giant receptors mediating endocytosis of multiple ligands.

Authors:  S K Moestrup
Journal:  Biochim Biophys Acta       Date:  1994-06-29

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis.

Authors:  Karin List; Christian C Haudenschild; Roman Szabo; WanJun Chen; Sharon M Wahl; William Swaim; Lars H Engelholm; Niels Behrendt; Thomas H Bugge
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

6.  Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation.

Authors:  Sarah Netzel-Arnett; Brooke M Currie; Roman Szabo; Chen-Yong Lin; Li-Mei Chen; Karl X Chai; Toni M Antalis; Thomas H Bugge; Karin List
Journal:  J Biol Chem       Date:  2006-09-15       Impact factor: 5.157

7.  MT-SP1 proteolysis and regulation of cell-microenvironment interactions.

Authors:  Molly R Darragh; Ami S Bhatt; Charles S Craik
Journal:  Front Biosci       Date:  2008-01-01

Review 8.  Zymogen activation, inhibition, and ectodomain shedding of matriptase.

Authors:  Chen-Yong Lin; I-Chu Tseng; Feng-Pai Chou; Sheng-Fang Su; Ya-Wen Chen; Michael D Johnson; Robert B Dickson
Journal:  Front Biosci       Date:  2008-01-01

9.  Matriptase activation, an early cellular response to acidosis.

Authors:  I-Chu Tseng; Han Xu; Feng-Pai Chou; Gong Li; Alexander P Vazzano; Joseph P Y Kao; Michael D Johnson; Chen-Yong Lin
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

10.  Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease.

Authors:  Antoine Désilets; François Béliveau; Guillaume Vandal; François-Olivier McDuff; Pierre Lavigne; Richard Leduc
Journal:  J Biol Chem       Date:  2008-02-08       Impact factor: 5.157

View more
  4 in total

Review 1.  Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression.

Authors:  Nisha R Pawar; Marguerite S Buzza; Toni M Antalis
Journal:  Cancer Res       Date:  2019-01-04       Impact factor: 12.701

2.  Prostasin is required for matriptase activation in intestinal epithelial cells to regulate closure of the paracellular pathway.

Authors:  Marguerite S Buzza; Erik W Martin; Kathryn H Driesbaugh; Antoine Désilets; Richard Leduc; Toni M Antalis
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

3.  Detection of active matriptase using a biotinylated chloromethyl ketone peptide.

Authors:  Sine Godiksen; Christoffer Soendergaard; Stine Friis; Jan K Jensen; Jette Bornholdt; Katiuchia Uzzun Sales; Mingdong Huang; Thomas H Bugge; Lotte K Vogel
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 4.  The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.

Authors:  Lukas Wettstein; Frank Kirchhoff; Jan Münch
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.